Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | RAPGEF4 | Q8WZA2 | 4/20 | 0.39 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.35 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.35 |
| ▸ | CLK1 | P49759 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2295454 | 0.88 | MAP3K5 (0.45) | MAP3K5CYP11B1CYP11B2LRRK2APP | |
| SCHEMBL28842738 | 0.76 | MAP3K5 (0.52) | MAP3K5CYP11B1CYP11B2LRRK2APP | |
| SCHEMBL18924017 | 0.72 | RAPGEF4 (0.39) | RAPGEF4 | |
| SCHEMBL14427902 | 0.70 | CYP11B1 (0.57) | MAP3K5CYP11B1CYP11B2APPALDH1A3 | |
| SCHEMBL2289469 | 0.67 | MAPT (0.44) | — | |
| SCHEMBL14647252 | 0.65 | MAP3K5 (0.54) | MAP3K5CYP11B1CYP11B2LRRK2APP | |
| SCHEMBL1318544 | 0.65 | MAP3K5 (0.61) | MAP3K5LRRK2CSNK1DCLK1DYRK1A | |
| SCHEMBL2291146 | 0.64 | L3MBTL1 (0.42) | RAPGEF4 | |
| SCHEMBL21708014 | 0.64 | ALDH1A3 (0.82) | CYP11B1CYP11B2APPALDH1A3CLK1 | |
| SCHEMBL755503 | 0.63 | APP (0.46) | MAP3K5CYP11B1CYP11B2APPALDH1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258151-B2 | 3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors | MERCK PATENT GMBH (DE) | 2012-09-04 | — | — | US | disclosed |
| US-20110195991-A1 | 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195991-A1 | 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS | GLP1R, SLC5A1, SLC5A2 | MAP3K5 1158/4885CYP11B1 2023/4885CYP11B2 2669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.